Bausch + Lomb and Celldex Report Phase 2 Clinical Trial Failures

By Dr. Zubair Khalid, DVM, MS, PhD ·

Bausch + Lomb and Celldex Report Phase 2 Clinical Trial Failures

Bausch + Lomb and Celldex have each reported disappointing results from separate phase 2 clinical trials. Both companies disclosed the setbacks independently.

Celldex has terminated further work in the indication following the phase 2 failure. Bausch + Lomb, however, cited numerical improvements and exploratory analyses from its trial to support discussions about potentially advancing to phase 3.

The two companies did not release specific data points or statistical details in the initial announcements.

Context

Phase 2 trials test a drug’s efficacy and side effects in a larger patient group. A failure at this stage typically halts development, as Celldex chose to do. Bausch + Lomb’s decision to highlight numerical trends and exploratory findings signals an attempt to salvage the program, though regulators and investors often view such post-hoc analyses with caution. For the life-sciences sector, these results underscore the high risk of drug development, where even well-funded candidates can fail to meet endpoints.

Source: original report

Related articles